Kyiv Biotech News (Ukraine)

Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD.

There are many different drug targets expressed in brain tissue. The delivery of drugs to central nervous system (CNS) is complicated by blood brain barrier (BBB) which controls entry of drugs into CNS.

The preclinical drug-discovery process requires the screening of millions of small organic molecules to find a suitable lead compound for one ultimately successful outcome.

Biologically active molecule is a broad term comprising a variety of compounds possessing biological activity.Our company, OTAVA Ltd., provides a wide range of biologically active compounds modulating activity of distinct targets.

In recent years, remarkable progress has been made and miraculous results produced in the field of synthetic chemistry. However, searching for desired chemical compounds among variety of chemical databases becomes more and more complex.

The challenging question of the modern pharmaceutical industry is why do fragments hits provide a new paradigm for drug discovery of some targets? In this white paper we describe the advantages of the fragment-based approach in search for new drugs.

The objective of this report is to give some insight on using chemical building blocks that allow generating diversity and complexity in chemical structures.

Using special focused libraries of chemical compounds in drug design is becoming increasingly common. Here we describe different kinds of focused compound libraries that can be used in medicinal chemistry.

To identify promising leads for potentially marketable drugs requires large compound libraries. In this white paper we would like to discuss some aspects of high-throughput screening (HTS) compound libraries used in drug discovery process.

OTAVA Ltd. offers a new set of target-focused libraries with Enhanced Intellectual Property Potential (EIPL®).

The libraries have been designed with QSAR and contain only drug-like compounds. These libraries are proposed for drug development.

Otava has various inhibitors, agonists and other biologically active compounds. Our company offers additional 30% discount on orders of our best selling products. A full list of available compounds on www.otavachemicals.com

Otava releases two GPCR-related focused libraries. The libraries have been designed with QSAR using training set. These libraries are proposed for screening in GPCR-associated research and drug development.

Otava pleased to offer two novel fluorescent dyes. This dyes developed using our innovative "lead dye" method.

Otava presents the new p38 MAP Kinase Alpha focused library. This p38 MAP Kinase Alpha focused library is an excellent and essential starting point in a drug discovery program.

Otava presents the new CDK2 focused library. This CDK2 focused library is an excellent and essential starting point in a drug discovery program.

Otava presents the new proto-oncogene tyrosine-protein kinase ABL1 focused library. This ABL1 focused library is an excellent and essential starting point in a drug discovery program.

New technology for virtual screening improving

ZORG UKRAINE and ILCI (Ankara, Turkey) launched a construction project of a biogas plant, designed to process wastes of a dairy farm, owned by ILCI. Two companies signed a contract on 26.05.06.

“ZORG UKRAINE” has started an exclusive engineering project of a biogas plant for a local Ukrainian company “Zeleny Gai,” allocated in Mykolaivsky region. General intention is for the plant to use corn and perennial native-grasses silo.